23165-46-0

Usage

Uses

Used in Chemical Research and Development:
2,4,5-Trichlorophenyl isothiocyanate is used as a reagent in chemical synthesis for the preparation of biologically active compounds. Its unique structure and reactivity make it an important building block in organic chemistry, contributing to the development of new chemical entities with potential applications in various fields.
Used in Pesticides and Fungicides:
As a member of the isothiocyanate class, 2,4,5-Trichlorophenyl isothiocyanate is utilized in the formulation of pesticides and fungicides. Its potent irritant properties and ability to inhibit the growth of pests and fungi make it a valuable component in agricultural and horticultural applications.
Used in Pharmaceutical Intermediates:
2,4,5-Trichlorophenyl isothiocyanate is employed as a pharmaceutical intermediate, playing a crucial role in the synthesis of various drugs. Its versatility and reactivity enable the development of new pharmaceutical compounds with potential therapeutic benefits.

InChI:InChI=1/C7H2Cl3NS/c8-4-1-6(10)7(11-3-12)2-5(4)9/h1-2H

Upstream product

• 463-71-8 thiophosgene 
• 636-30-6 2,4,5-trichloroaniline 
• 75-15-0 carbon disulfide 

Downstream Products

• 90617-76-8 1-(2,4,5-trichlorophenyl)thiourea 
• 1158838-80-2 1-(2,4,5-trichlorophenyl)-3-(3-oxo-1,3-dihydroisobenzofuran-5-yl)thiourea 
• 1039944-24-5 4-(2,4,5-trichlorophenyl)-3-thiosemicarbazide 
• 127142-43-2 C₁₅H₁₃Cl₃N₆S₂ 
• 1350545-22-0 8-(2,4,5-trichlorophenylamino)-9-cyclopentyl-2-(4-(4-methylpiperazin-1-yl)phenylamino)-9H-purine 

Relevant academic research and scientific papers

Discovery of dual inhibitors targeting both HIV-1 capsid and human cyclophilin A to inhibit the assembly and uncoating of the viral capsid

HIV-1 assembly and disassembly (uncoating) processes are critical for the HIV-1 replication. HIV-1 capsid (CA) and human cyclophilin A (CypA) play essential roles in these processes. We designed and synthesized a series of thiourea compounds as HIV-1 assembly and disassembly dual inhibitors targeting both HIV-1 CA protein and human CypA. The SIV-induced syncytium antiviral evaluation indicated that all of the inhibitors displayed antiviral activities in SIV-infected CEM cells at the concentration of 0.6-15.8 μM for 50% of maximum effective rate. Their abilities to bind CA and CypA were determined by ultraviolet spectroscopic analysis, fluorescence binding affinity and PPIase inhibition assay. Assembly studies in vitro demonstrated that the compounds could potently disrupt CA assembly with a dose-dependent manner. All of these molecules could bind CypA with binding affinities (Kd values) of 51.0-512.8 μM. Fifteen of the CypA binding compounds showed potent PPIase inhibitory activities (IC50 values 1 μM) while they could not bind either to HIV-1 Protease or to HIV-1 Integrase in the enzyme assays. These results suggested that 15 compounds could block HIV-1 replication by inhibiting the PPIase activity of CypA to interfere with capsid disassembly and disrupting CA assembly.